Imipenem, cilastatin, and relebactam

(Recarbrio®)

Imipenem, cilastatin, and relebactam

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 1.25 g/vial)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
  • Indicated in patients 18 years of age and older for the treatment of complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options.
  • Indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options.